Structure-activity relationship and pharmacokinetic studies of sotrastaurin (aeb071), a promising novel medicine for prevention of graft rejection and treatment of psoriasis

Journal of Medicinal Chemistry

Volumn 54, Issue 17, 2011, Pages 6028-6039

  Wagner, Jürgen ^a   Von Matt, Peter ^a   Faller, Bernard ^a   Cooke, Nigel G ^a   Albert, Rainer ^a   Sedrani, Richard ^a   Wiegand, Hansjörg ^a   Jean, Christian ^a   Beerli, Christian ^a   Weckbecker, Gisbert ^a   Evenou, Jean Pierre ^a   Zenke, Gerhard ^a   Cottens, Sylvain ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

SOTRASTAURIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG UPTAKE; GRAFT REJECTION; HUMAN; HUMAN CELL; IN VIVO STUDY; LYMPHOID TISSUE; MALE; MOUSE; NONHUMAN; PHYSICAL CHEMISTRY; PSORIASIS; RAT; STRUCTURE ACTIVITY RELATION; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME;

ANIMALS; CELLS, CULTURED; GRAFT REJECTION; HUMANS; LYMPHOCYTE ACTIVATION; MACACA FASCICULARIS; MICE; MICE, INBRED BALB C; PROTEIN KINASE C; PROTEIN KINASE INHIBITORS; PSORIASIS; PYRROLES; QUINAZOLINES; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; TISSUE DISTRIBUTION;

EID: 80052373772     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm200469u     Document Type: Article

References (27)

1. Dumont, F. J. Immunosuppressive strategies for prevention of transplant rejection Expert Opin. Ther. Pat. 2001, 11, 377-404 (Pubitemid 32186222)
2. Halloran, P. F. Immunosuppressive drugs for kidney transplantation N. Engl. J. Med. 2004, 351, 2715-2729 (Pubitemid 39665325)
3. Liu, E. H.; Siegel, R. M.; Harlan, D. M.; O'shea, J. J. T cell-directed therapies: lessons learned and future prospects Nat. Immunol. 2007, 8, 25-30 (Pubitemid 46242355)
4. Wagner, J.; von Matt, P.; Sedrani, R.; Albert, R.; Cooke, N.; Ehrhardt, C.; Geiser, M.; Rummel, G.; Stark, W.; Strauss, A.; Cowan-Jacob, S. W.; Beerli, C.; Weckbecker, G.; Evenou, J.-P.; Zenke, G.; Cottens, S. Discovery of 3-(1 H -indol-3-yl)-4-[2-(4-methylpiperazin-1-yl)quinazolin-4-yl]-pyrrole-2,5-dione (AEB071), a potent and selective inhibitor of protein kinase C isotypes J. Med. Chem. 2009, 52, 6193-6196
5. Evenou, J.-P.; Wagner, J.; Zenke, G.; Brinkmann, V.; Wagner, K.; Kovarik, J.; Welzenbach, K. A.; Weitz-Schmidt, G.; Guntermann, C.; Towbin, H.; Cottens, S.; Kaminski, S.; Letschka, T.; Lutz-Nicoladoni, C.; Gruber, T.; Hermann-Kleiter, N.; Thuille, N.; Baier, G. The potent protein kinase C selective inhibitor AEB071 (sotrastaurin) represents a new class of immunosuppressive agents affecting early T cell activation J. Pharmacol. Exp. Ther. 2009, 330, 792-801
6. Skvara, H.; Dawid, M.; Kleyn, E.; Wolff, B.; Meingassner, J. G.; Knight, H.; Dumortier, T.; Kopp, T.; Fallahi, N.; Stary, G.; Burkhart, C.; Grenet, O.; Wagner, J.; Hijazi, Y.; Morris, R. M.; McGeown, C.; Rordorf, C.; Griffiths, C. E. M.; Stingl, G.; Jung, T. The PKC inhibitor AEB071 may be a therapeutic option for psiorasis J. Clin. Invest. 2008, 118, 3151-3159
7. Budde, K.; Sommerer, C.; Becker, T.; Asderakis, A.; Pietruck, F.; Grinyo, J. M.; Rigotti, P.; Dantal, J.; Ng, J.; Barten, M. J.; Weber, M. Sotrastaurin, a novel small molecule inhibiting protein kinase C: first clinical results in renal-transplant recipients Am. J. Transpl. 2010, 10, 571-581
8. Newton, A. C. Regulation of the ABC kinases by phosphorylation: protein kinase C as a paradigm Biochem. J. 2003, 370, 361-371 (Pubitemid 36315124)
9. Tan, S.-L.; Parker, P. J. Emerging and diverse roles of protein kinase C in immune cell signalling Biochem. J. 2003, 376, 545-552 (Pubitemid 38058054)
10. Baier, G. The PKC gene module: molecular biosystematics to resolve its T cell function Immunol. Rev. 2003, 192, 64-79 (Pubitemid 36613324)
11. Guo, B.; Su, T. T.; Rawlings, D. J. Protein kinase C family functions in B-cell activation Curr. Opin. Immunol. 2004, 16, 367-373 (Pubitemid 38595376)
12. +)-ATPase. 5. Substituted 2,4-diaminoquinazolines and thienopyrimidines J. Med. Chem. 1995, 38, 2763-2773
13. Faul, M. M.; Winneroski, L. L.; Krumrich, C. A. A new, efficient method for the synthesis of bisindolylmaleimides J. Org. Chem. 1998, 63, 6053-6058
14. Kosugi, M.; Negishi, Y.; Kameyama, M.; Migita, T. Palladium-catalyzed displacement of aryl halide by tin analogue of Reformatsky reagent Bull. Chem. Soc. Jpn. 1985, 58, 3383-3384
15. Wolfe, J. P.; Buchwald, S. L. Palladium-catalyzed amination of aryl triflates J. Org. Chem. 1997, 62, 1264-1267 (Pubitemid 127493300)
16. Jagdmann, G. E.; Munson, H. R.; Gero, T. W. A mild efficient procedure for the conversion of carboxylic acid esters to primary amides using formamide/methanolic sodium methoxide Synth. Commun. 1990, 20, 1203-1208
17. 2A receptor antagonists Bioorg. Med. Chem. 2001, 9, 2129-2137 (Pubitemid 32739200)
18. Kovarik, J. M.; Huang, H.-L. A.; Slade, A.; Sfikas, N.; Chandler, P. A. The effect on sotrastaurin pharmacokinetics of strong CYP3A inhibition by ketoconazole Br. J. Clin. Pharmacol. 2009, 68, 381-385
19. Choc, M. G.; Mueller, E. A.; Robinson, W. T.; Kuhmle, A.; Smith, H. T.; Charnick, S. B. Relative bioavailability of Neoral versus Sandimmun in the presence of a P450IIIA and P-glycoprotein inhibitor Transplant Proc. 1998, 30, 1664-1665 (Pubitemid 28399270)
20. Weckbecker, G.; Pally, C.; Beerli, C.; Burkhart, C.; Wieczorek, G.; Metzler, B.; Morris, R. E.; Wagner, J.; Bruns, C. Effects of the novel protein kinase C inhibitor AEB071 (sotrastaurin) on rat cardiac allograft survival using single agent treatment or combination therapy with cyclosporine, everolimus or FTY720 Transpl. Int. 2010, 23, 543-552
21. For experimental details, see the following: Suomalainen, P.; Johans, C.; Soederlund, T.; Kinnunen, P. K. J. Surface activity profiling of drugs applied to the prediction of blood-brain barrier permeability J. Med. Chem. 2004, 47, 1783-1788 (Pubitemid 38380922)
22. Frenkel, Y. V.; Clark, A. D.; Das, K.; Wang, Y.-H.; Lewi, P. J.; Janssen, P. A. J.; Arnold, E. Concentration and pH dependent aggregation of hydrophobic drug molecules and relevance to oral bioavailability J. Med. Chem. 2005, 48, 1974-1983 (Pubitemid 40396326)
23. Porter, C. J. H.; William, N. Transport and absorption of drugs via the lymphatic system Adv. Drug Delivery Rev. 2001, 50, 1-2 (Pubitemid 32727273)
24. Wasan, K. M. The role of lymphatic transport in enhancing oral protein and peptide drug delivery Drug Dev. Ind. Pharm. 2002, 28, 1047-1058 (Pubitemid 35278830)
25. 4 receptor inverse agonists using a scaffold hopping approach J. Med. Chem. 2008, 51, 7855-7865
26. Dawson, M. I.; Ye, M.; Cao, X.; Farhana, L.; Hu, Q.-Y.; Zhao, Y.; Xu, L. P.; Kiselyuk, A.; Correa, R. G.; Yang, L.; Hou, T.; Reed, J. C.; Itkin-Ansar, P.; Levine, F.; Sanner, M. F.; Fontana, J. A.; Zhang, X.-K. Derivation of a retinoid X receptor scaffold from peroxisome proliferator-activated receptor γ ligand 1-di(1 H -indol-3-yl)methyl-4-trifluoromethylbenzene ChemMedChem 2009, 4, 1106-1119
27. Ilovich, O.; Billauer, H.; Dotan, S.; Mishani, E. Labeled 3-aryl-4-indolylmaleimide derivatives and their potential as angiogenic PET biomarkers Bioorg. Med. Chem. 2010, 18, 612-620